Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort ascending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xtandi Enzalutamide Metastatic Castration Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete
Xtandi Enzalutamide mHSPC Reimburse with clinical criteria and/or conditions Complete
N/A enzalutamide Genito-urinary cancer (prostate cancer) Open for Stakeholder Input
Rozlytrek entrectinib Extracranial solid tumours with NTRK gene fusion Reimburse with clinical criteria and/or conditions Complete
TBD Entrectinib Withdrawn
Rozlytrek Entrectinib ROS1-positive NSCLC Reimburse with clinical criteria and/or conditions Complete
Baraclude Entecavir Hepatitis B (chronic) List with clinical criteria and/or conditions Complete
Padcev enfortumab vedotin Metastatic urothelial cancer Pending
Padcev enfortumab vedotin Locally advanced or metastatic urothelial carcinoma Reimburse with clinical criteria and/or conditions Complete
Braftovi and Mektovi encorafenib and binimetinib Advanced Melanoma Reimburse with clinical criteria and/or conditions Complete